title: Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117, and myeloperoxidase.
abstract: BACKGROUND
  Immunophenotyping of bone marrow (BM) specimens with acute myelogenous leukemia (AML) may be performed by flow cytometric (FC) or immunohistochemical (IH) techniques. Some markers (CD34, CD15, and CD117) are available for both techniques. Myeloperoxidase (MPO) analysis may be performed by enzyme cytochemical (EC) or IH techniques.
  
  
  OBJECTIVE
  To determine the reliability of these markers and MPO by these techniques, we designed a study to compare the results of analyses of these markers and MPO by FC (CD34, CD15, and CD117), EC (MPO), and IH (CD34, CD15, CD117, and MPO) techniques.
  
  
  METHODS
  Twenty-nine AMLs formed the basis of the study. These AMLs all had been immunophenotyped previously by FC analysis; 27 also had had EC analysis performed. Of the AMLs, 29 had BM core biopsies and 26 had BM clots that could be evaluated. The paraffin blocks of the 29 BM core biopsies and 26 BM clots were stained for CD34, CD117, MPO, and CD15. These results were compared with results by FC analysis (CD34, CD15, and CD117) and EC analysis (MPO).
  
  
  RESULTS
  Immunodetection of CD34 expression in AML had a similar sensitivity by FC and IH techniques. Immunodetection of CD15 and CD117 had a higher sensitivity by FC analysis than by IH analysis. Detection of MPO by IH analysis was more sensitive than by EC analysis. There was no correlation of French-American-British (FAB) subtype of AML with CD34 or CD117 expression. Expression of CD15 was associated with AMLs with a monocytic component. Myeloperoxidase reactivity by IH analysis was observed in AMLs originally FAB subtyped as M0.
  
  
  CONCLUSIONS
  CD34 can be equally detected by FC and IH techniques. CD15 and CD117 are better detected by FC analysis and MPO is better detected by IH analysis.
authors.affiliation: Division of Hematopathology, Department of Pathology, St Louis University Health Sciences Center, St Louis, MO, USA. cdunphy@unch.unc.edu
authors.forename: C H
authors.initials: CH
authors.lastname: Dunphy
authors.forename: J M
authors.initials: JM
authors.lastname: Polski
authors.forename: H L
authors.initials: HL
authors.lastname: Evans
authors.forename: L J
authors.initials: LJ
authors.lastname: Gardner
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D001853:Bone Marrow / Q000201:enzymology / Q000276:immunology* / Q000473:pathology; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology / Q000276:immunology* / Q000473:pathology; D016256:Lewis X Antigen / Q000032:analysis*; D010232:Paraffin; D009195:Peroxidase / Q000032:analysis*; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis*; D012680:Sensitivity and Specificity; D016610:Tissue Embedding
chemical_list: D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D016256:Lewis X Antigen; D010232:Paraffin; D009195:Peroxidase; D019009:Proto-Oncogene Proteins c-kit